SLNO: Major Lawsuit Filed — What You Need to Know Now!

Dividend Policy & Cash Flows

No Dividend History: Soleno has never paid a dividend. This is typical for a growth-stage biotech; all cash is reinvested into operations or shareholder buybacks. Current dividend yield is 0% (www.cnbc.com). Metrics like AFFO/FFO (used for REITs) are not applicable here. Instead, investors should focus on Soleno’s operating cash flow and net income.

Positive Cash Generation: With VYKAT XR’s launch, Soleno’s cash flow turned positive. The company generated $48.7 million of operating cash in Q4 2025 (investors.soleno.life), contributing to full-year net income of ~$20.9 million (investors.soleno.life). Management even initiated a $100 million accelerated share repurchase in late 2025 (investors.soleno.life) – a strong vote of confidence that excess cash was better used to retire stock. After this buyback, Soleno still ended 2025 with $506.1 million in cash and investments (investors.soleno.life). This hefty cash war chest provides flexibility to fund growth or withstand legal/regulatory challenges.

Leverage & Debt Maturities

Low Leverage: Soleno carries minimal debt relative to its cash. As of mid-2025, the company had $50 million drawn under a loan facility with Oxford Finance (www.sec.gov). This credit line can expand up to $200 million as milestones are met, but Soleno hasn’t needed to tap much of it due to equity raises and product revenues. Year-end 2025 net cash was roughly $456 million (cash $506M minus debt $50M), so Soleno has no net-debt burden.

Debt Terms: The Oxford loan is 5-year term debt (entered Dec 2024) with an initial 48-month interest-only period (www.sec.gov). Maturity is expected around late 2029 (extendable 12 months if performance milestones are hit) (www.sec.gov). Interest accrues at 1-month SOFR + 5.50% (currently around ~10–11% annual) (www.sec.gov). While the rate is high, interest coverage is not a concern – Soleno’s interest income on its cash (~$5.3M in Q3 2025) far exceeded its interest expense (~$1.4M) that quarter (investors.soleno.life). In other words, the company’s cash pile is generating more interest than it pays out, and operating EBITDA is comfortably positive. Debt covenants are standard and have not been an issue (www.sec.gov). Overall, Soleno’s financial leverage is modest and well-managed, with no near-term maturities pressing.

Coverage and Liquidity

Liquidity Position: Soleno’s liquidity is very strong. Current assets were $535M vs. $92M total liabilities as of Q3 2025 (investors.soleno.life). The company should have ample liquidity to fund ongoing commercialization and any legal costs from the new lawsuit. Additionally, Soleno expanded its ATM (“at-the-market”) equity program in 2024 and raised $230M in a mid-2025 stock offering (investors.soleno.life), so it has a history of accessing capital markets opportunistically. With positive cash flow now, dilution needs should be minimal.

Dividend Coverage: Since there is no dividend, payout coverage isn’t applicable. Instead, Soleno has used cash for buybacks. In November 2025, management spent $100M on stock repurchases, reflecting confidence in the company’s valuation (investors.soleno.life). That said, returning capital to shareholders at this early stage is somewhat unusual for a biotech. Investors should monitor whether Soleno continues buybacks (which could bolster the stock) or conserves cash if challenges emerge.

Valuation & Share Performance

Stock Surge and Pullback: Soleno’s stock soared in 2025 following FDA approval of VYKAT XR. By mid-2025, shares traded in the high double-digits, and the company’s market cap peaked well above $2 billion. In fact, one analyst had a Street-high target of $115 during the euphoria (sa.marketscreener.com). The initial commercial traction was impressive – Soleno captured ~12% of the PWS market in 9 months (investors.soleno.life) – driving bullish sentiment. The stock hit an all-time high around the launch but dramatically pulled back in H2’25 as safety concerns surfaced (more on that below). As of April 2026, Soleno’s market cap sits around $2.1 billion (www.fool.com), with the stock near $50 per share.

Multiples: At ~$50, Soleno trades at roughly 10–11× trailing sales (www.tipranks.com) and a rich triple-digit P/E on 2025 GAAP earnings (which were only ~$0.40/share due to heavy upfront costs). This valuation assumes continued growth and a relatively smooth commercialization. By comparison, established pharma companies trade at ~4–6× sales, but fast-growing orphan drug biotechs often command premium multiples. If VYKAT XR adoption continues expanding and profits scale up, Soleno’s forward P/E would drop quickly. However, recent events have injected uncertainty, so the market is re-rating Soleno more cautiously. In early April 2026, no fewer than four firms – Baird, Oppenheimer, Stifel, and Cowen – downgraded SLNO to neutral/hold and slashed their price targets to ~$53 (sa.marketscreener.com). This cluster of downgrades suggests that Wall Street now views Soleno’s risk/reward as more balanced at current prices.

Peer Comparison: There are few direct comparables (Soleno is the first to market in PWS). One relevant peer group is orphan-disease biotechs that launched a single product. Many trade at 8–12× sales in their first year of launch, similar to Soleno’s range. The premium valuation reflects Soleno’s unique market position (no approved competitors for PWS hyperphagia) and the potential for global expansion (an EU approval application was filed in 2025). Investors are effectively pricing in a successful U.S. rollout and future growth – but not without reservation given the safety cloud and lawsuit.

Major Lawsuit and Alleged Misconduct

Class Action Filed: In March 2026, a shareholder class action was filed (City of Pontiac Police & Fire Retirement System v. Soleno Therapeutics) alleging securities fraud during Mar 26 – Nov 4, 2025 (www.prnewswire.com). The core claim is that Soleno and its executives made materially false or misleading statements and omitted adverse facts about the Phase 3 clinical program for DCCR (www.globenewswire.com) (www.prnewswire.com). Specifically, the complaint alleges Soleno downplayed or hid evidence of significant safety concerns in the trial – particularly excess fluid retention in patients – which would imply higher risks (e.g. heart failure, need for discontinuation, regulatory pushback) than the company let on (www.prnewswire.com). By overstating DCCR’s safety and prospects, Soleno supposedly painted an overly rosy picture that inflated its stock price.

Revelations and Stock Impact: The “truth” began to emerge in Q3 2025. On August 15, 2025, short-seller Scorpion Capital published a scathing 415-page report accusing Soleno of deadly safety issues and fraud (hk.marketscreener.com). Scorpion cited a “rapid pile-up” of reports of children being hospitalized for potential heart failure shortly after starting VYKAT XR (hk.marketscreener.com). The report even warned VYKAT XR might be pulled from the market due to safety, and claimed new prescriptions could “plunge” (www.globenewswire.com). It also alleged Soleno’s initial launch metrics were ‘hocus-pocus,’ propped up by a single “controversial” physician in Florida who was a lead trial investigator and an outsized prescriber (hk.marketscreener.com). Moreover, Scorpion asserted that Soleno’s clinical trials were essentially a “sham” – pointing to suspicious data patterns and ex-employees’ accounts that cast doubt on the integrity of trial results and FDA submissions (hk.marketscreener.com).

These bombshell allegations immediately hit the stock: shares fell 8% on Aug 15, 2025 as investors reacted (hk.marketscreener.com) (hk.marketscreener.com). Then on September 10, 2025, Soleno disclosed via the FDA adverse event database that a patient death had occurred in a child taking VYKAT XR (hk.marketscreener.com). This tragedy (and its confirmation of Scorpion’s warnings) sent the stock down another 12% that day (hk.marketscreener.com) (hk.marketscreener.com). By early November 2025, Soleno had to acknowledge the impact of the controversy – fewer new patient starts and increased drop-offs after the Scorpion report’s publication (www.prnewswire.com). When Soleno reported Q3 results on Nov 4, 2025, management admitted that the short-seller’s report caused a “disruption” in the launch trajectory, rattling the PWS community (www.prnewswire.com). On this news, SLNO shares plunged over 26% in one day (www.prnewswire.com).

Legal Stakes: The class action seeks to prove that Soleno knew about these safety problems all along (from the trial phase) and misrepresented or failed to disclose them, thus deceiving investors. If successful, Soleno could face damages or a settlement – though it’s early in the process (lead plaintiff motions are due by May 5, 2026) (www.prnewswire.com). Such lawsuits typically take years to resolve. It’s worth noting that multiple law firms (Kessler Topaz, Robbins Geller, Hagens Berman, Rosen Law, etc.) have announced investigations or filings, indicating significant shareholder losses in that class period. Insurance usually covers much of the settlement cost in securities cases, so the financial penalty may be manageable, but the reputational damage and management distraction are real factors.

Operating Fundamentals & Outlook

Product Uptake vs. Safety Concerns: Despite the turmoil, Soleno’s underlying business showed strong early uptake. By December 2025, 859 patients were on VYKAT XR therapy (roughly 8–10% of all U.S. PWS patients) (investors.soleno.life) (investors.soleno.life). Net revenue in Q4 2025 reached $91.7M, up +39% sequentially (investors.soleno.life), which underscores robust demand if the drug is deemed safe and accessible. However, safety is the wildcard. Soleno reports that about 15% of patients have discontinued VYKAT XR, with ~12% discontinuing specifically due to adverse events (side effects) (www.fool.com) (www.fool.com). Management expects long-term discontinuation rates around 15–20% (www.fool.com), which they portray as reasonable for a chronic therapy. The most common side effect observed is fluid retention/edema (consistent with diazoxide’s known profile), which in rare cases can strain the heart. Indeed, Soleno’s CEO has emphasized that many patients have been on drug >1 year with no new safety signals, arguing that the overall benefit/risk remains favorable (investors.soleno.life) (investors.soleno.life).

Still, the short-seller’s claims of “heart failure” incidents and a fatality cannot be taken lightly. The FDA could impose additional safety requirements – for example, a “black box” warning about edema/cardiac risk, or a risk mitigation program (monitoring patients for cardiac issues). Any such action might slow down new prescriptions as doctors and families become more cautious. Furthermore, European regulators (EMA) are reviewing Soleno’s drug now – it’s possible the EMA could delay approval or require stricter safety data, given the controversy. For 2026, investors should watch prescription trends each quarter: Q4 2025 saw a notable drop in new patient start forms (only 207 in Q4 vs. ~397 in Q3) (investors.soleno.life). Management partly blamed year-end seasonality and insurance reauthorization delays, but it coincided with the safety scare. If growth in active patients stalls or discontinuations accelerate above 20%, it may signal that safety concerns are indeed curbing the drug’s uptake.

Financial Sustainability: On the positive side, Soleno’s profitability and cash cushion give it resilience. The company achieved $26M net income in Q3 2025 alone (investors.soleno.life) (investors.soleno.life), and ended 2025 with $20.9M full-year profit (investors.soleno.life) despite heavy launch investments. Gross margins on VYKAT XR are high (the drug costs little to manufacture relative to its orphan pricing). Even if Soleno were forced to spend more on safety studies or litigation, it can likely absorb those costs without jeopardizing operations. Also, the absence of competing therapies for PWS hyperphagia means Soleno can continue to grow its franchise if it effectively manages the risk perceptions. The company has been expanding insurance coverage (185+ million covered lives by Dec 2025) (investors.soleno.life) and physician awareness. It’s broadening prescriber base – 630 unique prescribers have written VYKAT XR so far (investors.soleno.life), up from 131 in the first quarter (investors.soleno.life). This indicates that reliance on any single physician (despite Scorpion’s claims) should diminish over time as more clinics adopt the therapy.

Pipeline & Strategy: A concern is that Soleno is currently a one-product company. Scorpion Capital bluntly called Soleno a “one-trick pony” with “no other meaningful assets, pipeline, or scientific program” (www.globenewswire.com). This means the company’s fortunes are almost entirely tied to VYKAT XR. Notably, Soleno’s core patent on DCCR expires in 2026 (www.globenewswire.com), though FDA orphan drug exclusivity protects it from direct competition in PWS until 2032. Soleno has signaled plans to expand DCCR into additional rare diseases and pursue approvals abroad (investors.soleno.life). The specifics remain to be seen – possible indications could include other genetic obesity or hyperphagic disorders. These initiatives could open new markets, but they will take time (and trials) to materialize. In the meantime, Soleno’s leadership must maintain momentum in PWS while navigating the safety scrutiny.

Key Risks, Red Flags & Unknowns

– Safety/Regulatory Risks: The top risk is that VYKAT XR’s safety profile is worse than anticipated. Reports of severe edema and a pediatric death have emerged (hk.marketscreener.com) (hk.marketscreener.com). If further adverse events (e.g. heart failure cases) occur, the FDA could enforce new warnings, restrict usage to certain patients, or even suspend the drug. Such actions would sharply derail sales. Ongoing safety surveillance is critical; investors should monitor FDA communications and any updates to the drug’s label.

– Lawsuit & Management Credibility: The class action alleges that Soleno misled investors about safety. While the outcome is uncertain, the allegations raise red flags about management’s transparency. Were early warning signs (like fluid retention issues in trials) downplayed? Internal documents or whistleblowers could surface during litigation. Even if Soleno prevails legally, management’s credibility will be under the microscope. Any hint of dishonesty or data manipulation could permanently damage investor and physician trust. Conversely, a quick dismissal of the lawsuit would be a positive signal. This will be a long saga, and it adds an overhang on the stock.

– Single Product Dependence: Soleno’s entire valuation rests on one therapy for one rare disease. This concentration amplifies the impact of any problem with the product. No diversification means higher risk – if VYKAT XR falters (due to safety, competition, or limited market uptake), Soleno has no other revenue streams to fall back on. The patent expiry in 2026 is also notable (www.globenewswire.com), because although orphan exclusivity in the U.S. delays generic competition, payers could push back on price over time. Generic diazoxide (an older formulation) exists for other uses – some physicians might attempt off-label use as a cheaper alternative, though it’s not ideal for PWS. Soleno urgently needs to build a pipeline or in-license new assets to reduce its single-product risk. Management has cash to deploy, so investors will be watching for business development moves in 2026.

– Commercial Execution: While the launch was strong out of the gate, recent trends raise questions about sustained growth. New patient starts slowed in Q4 2025 (investors.soleno.life). It’s unclear if this is a temporary blip or an early sign of market saturation or caution. Prader-Willi syndrome is an ultra-orphan condition (~10–20k patients in the U.S.), so there is a finite market size. Soleno captured ~12% of the addressable market in 2025 (investors.soleno.life) – reaching the remaining patients may be harder, especially if some families are hesitant due to side effects or cost. Discontinuation rates will be important: Soleno expects 15–20% long-term dropout (www.fool.com), but if this creeps higher, it could indicate tolerability or adherence issues. Additionally, by Soleno’s own admission, one prescribing physician had an outsized role early on (hk.marketscreener.com). If that “power user” was driving many start forms (as Scorpion insinuates), the company must broaden its prescriber base to keep growth coming. The good news is, 600+ doctors have prescribed so far (investors.soleno.life), diluting any single prescriber’s influence. Still, salesforce execution and physician education are key – Soleno needs to reassure the medical community about safety and convince them of the drug’s benefits (improved behavior, quality of life in PWS patients). Any stumble in these outreach efforts could slow adoption.

– International and Expansion Risks: Soleno’s growth plan includes international approvals (starting with Europe) and potentially new indications. Both come with risk. Europe’s regulators might scrutinize DCCR’s risk/benefit profile even more rigorously, given the U.S. post-marketing events. Approval in the EU is not guaranteed, or could require extra safety studies. New indication development could divert resources and isn’t a sure bet scientifically. Investors should be cautious about baking in foreign revenue or pipeline upside until more concrete progress is made.

– Macro and Other Factors: As a newly profitable biotech, Soleno may start to be affected by broader trends like drug pricing pressure. VYKAT XR is undoubtedly expensive (likely priced in the mid-six-figures annually per patient, given $190M revenue for ~1,000 patients). Insurers have largely covered it so far (185M lives covered (investors.soleno.life)), but if outcomes disappoint or budget impact grows, payers could impose stricter prior authorizations or seek discounts. Additionally, insider actions bear watching – the short report questioned insider confidence, perhaps referencing any stock sales by executives. Any notable insider selling or conservative guidance could be red flags. On the flip side, insider buying or increased guidance would signal confidence that the worst of the issue is behind them.

Open Questions & What to Watch

– Will the lawsuit uncover evidence of wrongdoing? The class action will proceed through motions in 2026. Key questions are whether internal documents or whistleblower testimony show that Soleno’s execs knew of major safety issues (like serious edema/cardiac events) before the short-seller exposed them. If credible evidence emerges, it could not only hurt the stock but also attract regulatory scrutiny (SEC or DOJ). If the case is weak, it may eventually be dismissed – clearing a cloud over Soleno. Expect periodic news as legal deadlines approach (e.g. an amended complaint or a motion to dismiss ruling).

– Can Soleno restore confidence in VYKAT XR’s safety? Management insists the drug’s safety profile is “compelling” and “favorable” based on long-term trial data (investors.soleno.life). Investors need to see corroborating evidence in real-world use. Watch for updated safety data from the company – perhaps at medical conferences or in a Year-1 post-marketing report. If no new serious adverse trends emerge in 2026, it will bolster the case that the initial incidents were rare exceptions. Also important will be any FDA communications: the absence of FDA action would be a positive sign, whereas an FDA safety alert or label change would be a clear negative.

– How will growth trend in 2026? The next few quarters are critical. If Soleno resumes strong growth in patient starts and keeps discontinuations ~15–20%, it will validate robust demand and management’s mitigation of the short-seller fallout. On the Q4 earnings call, Soleno mentioned ongoing initiatives (broader caregiver engagement, case studies of patient “success stories”) to drive “sustained growth throughout 2026” (www.fool.com) (www.fool.com). We will see if these efforts pay off. Conversely, if Q1 or Q2 2026 sales come in flat or weak, it might indicate lingering damage from the safety scare or market saturation. Analysts currently expect growth, but perhaps at a more moderate pace. Any guidance provided by the company will be telling – Soleno has not given formal revenue guidance yet, so even directional commentary (e.g. “we expect continued sequential growth”) will be parsed.

– European approval and global plans: Keep an eye on Soleno’s EU marketing application for DCCR. A decision could come in late 2026 or 2027. Approval there would open a similar-sized market as the U.S. (Europe has an estimated PWS population on par with America’s). However, if EU regulators raise concerns (perhaps demanding additional safety data or advisory committee review), it might validate some of the safety worries. Additionally, any partnerships or licensing deals outside the U.S. would be a catalyst – Soleno might not commercialize overseas alone, so a co-marketing deal could bring non-dilutive capital. No such deal has been announced yet, but the strong U.S. launch might attract interest from larger rare-disease pharma companies.

– Pipeline development: Soleno has hinted at exploring DCCR in other rare disorders, leveraging its mechanism (modulating certain metabolic and neuroendocrine pathways). Investors should watch for any new trial announcements. If Soleno initiates a Phase 2 in another indication, it could create upside (diversifying the revenue potential). Conversely, a lack of pipeline progress by late 2026 would underscore that Soleno remains a one-product story – which could limit long-term upside and make the company more of a takeover candidate for big pharma rather than a standalone growth story.

– Management and governance: Lastly, assess how Soleno’s leadership navigates this challenging period. Thus far, they responded to the short report by doubling down on communications about efficacy/safety and buying back shares aggressively – actions meant to signal confidence. Going forward, will management remain transparent? Any unexpected executive departures or turnover could be a warning sign. Conversely, adding experienced independent directors (especially with compliance or pharmacovigilance expertise) would be a welcome step. Sometimes young biotechs stumble on commercialization, but Soleno’s team did achieve profitability quickly – they deserve some credit. The question is whether they can adeptly handle the reputational rehab now required.

Bottom Line: Soleno Therapeutics finds itself at a crossroads. On one hand, the company has achieved something rare – bringing an orphan drug to market, generating substantial revenue, and turning profitable within the first year of launch. On the other hand, serious allegations of misconduct and safety risks have cast a shadow over that success. Investors should stay vigilant: monitor the legal proceedings, track prescription and safety data each quarter, and listen for management updates on strategy. The upside is that if Soleno overcomes these challenges, the stock’s valuation (recently reset to ~$50s) could have room to run given the large unmet need in PWS and potential expansion. However, the downside risks – from litigation fallout or an FDA safety crackdown – cannot be ignored. At current levels, the market is cautiously balancing these factors, awaiting more clarity. “What you need to know now” is that the next few months will be pivotal in determining whether Soleno’s PWS franchise can continue to thrive, or whether the company becomes another case of a high-flying biotech tripped up by safety issues and trust erosion. Stay tuned.

Sources: Soleno SEC filings and press releases; Q4’25 earnings call transcript; class action lawsuit notices (Kessler Topaz, Hagens Berman) and Scorpion Capital report highlights (www.globenewswire.com) (www.prnewswire.com) (hk.marketscreener.com) (www.globenewswire.com) (www.fool.com).

For informational purposes only; not investment advice.